Welcome Visitor, Sign Up for Free!

Victoza Raises Concern for Incretin Mimetic Users

Victoza (liraglutide) is an incretin mimetic medication for treating type-2 diabetes. The FDA approved this GLP-1 receptor agonist by Novo Nordisk in January of 2010. But, when officials became concerned about the safety hazards associated with Victoza, manufacturers were forced to supply the medication with a black box warning.

Victoza Black Box Warning

Black box warnings by U.S. Food and Drug Administration indicate the highest level of warning for a medicine. For Novo’s Victoza, the warning was implemented after lab experiments in which mice were treated with the medication resulted in adverse reactions. According to reports, the mice developed thyroid cancers. The black box warning notifies patients of this risk and has contraindicated use of Victoza (liraglutide) in patients with a personal or family history of medullary thyroid cancer or multiple endocrine neoplasia syndrome. The update is shown below.

victoza black box warning

Furthermore, this twice-daily incretin mimetic was shown to have pancreatic affects causing pancreatitis and pancreatic cancer in patients. Nova Nordisk claims that these findings most likely only affect mice. Administration at Novo predict that similar medications will be found to have the same effects.

Similar Incretin Mimetics Byetta and Januvia

Despite the concerns with incretin mimetics, medications Byetta and Januvia have not been assigned black box warnings by the FDA- yet. In 2013, studies demonstrated that GP1 receptor agonist therapies increase the risk for developing pancreatic cancer more than twofold. Many have filed lawsuits against Merck & Co., and Eli Lilly & Co. and Amylin for misinformation and failure to warn patients about the serious threats related to incretin mimetics Januvia and Byetta. Bellwether trials for lawsuits against Januvia and Byetta manufacturers will take place in t he next few months.

Continue reading bad-drug.net to keep up with the latest medical information.